By using the annexin V/7-AAD assay, we found that SF treatment significantly increased early apoptosis in treated CSCs, which was equal to using 0.5 μg/ml CIS and greater than 1.3 μg/ml 5-FU. The gene discussed is ANXA5; the disease is in situ carcinoma.